NASDAQ · BEAT
Healthcare · Medical - Healthcare Information Services
$0.41
Up+$0.04 (+8.70%)
Updated Nov 3, 2026, 2:43 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BEAT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
BEAT closed at $0.41 after 21 trading sessions, down 37.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $0.56 | $0.5608 | $0.391 | $0.409 | 4.14M |
| Oct 30, 2026 | $0.54 | $0.559 | $0.52 | $0.55 | 1.7M |
| Oct 29, 2026 | $0.548 | $0.5748 | $0.5006 | $0.5389 | 2.48M |
| Oct 28, 2026 | $0.4148 | $0.5363 | $0.41 | $0.5318 | 5.52M |
| Oct 27, 2026 | $0.4078 | $0.41 | $0.39 | $0.4004 | 1.21M |
| Oct 26, 2026 | $0.392 | $0.4096 | $0.3813 | $0.4092 | 1.48M |
| Oct 23, 2026 | $0.396 | $0.4024 | $0.3857 | $0.3933 | 545.33K |
| Oct 22, 2026 | $0.4133 | $0.4133 | $0.392 | $0.3981 | 617.91K |
| Oct 21, 2026 | $0.42 | $0.4229 | $0.4004 | $0.407 | 373.33K |
| Oct 20, 2026 | $0.4108 | $0.425 | $0.403 | $0.4108 | 505.33K |
| Oct 19, 2026 | $0.443 | $0.443 | $0.4115 | $0.413 | 763.38K |
| Oct 16, 2026 | $0.4251 | $0.4388 | $0.4149 | $0.436 | 460.89K |
| Oct 15, 2026 | $0.4027 | $0.4399 | $0.4025 | $0.4315 | 1.22M |
| Oct 14, 2026 | $0.4085 | $0.4099 | $0.38 | $0.3929 | 994.64K |
| Oct 13, 2026 | $0.408 | $0.4139 | $0.3906 | $0.4018 | 1.55M |
| Oct 12, 2026 | $0.4771 | $0.4779 | $0.4201 | $0.425 | 1.4M |
| Oct 9, 2026 | $0.49 | $0.5099 | $0.471 | $0.4802 | 1.51M |
| Oct 8, 2026 | $0.517 | $0.5284 | $0.4873 | $0.4887 | 3.6M |
| Oct 7, 2026 | $0.588 | $0.615 | $0.5301 | $0.543 | 5.11M |
| Oct 6, 2026 | $0.6226 | $0.64 | $0.57 | $0.584 | 18.32M |
| Oct 5, 2026 | $0.75 | $0.95 | $0.60 | $0.6542 | 404.24M |
The latest Smart Investors Daily articles mentioning BEAT.
Company
Market Activity
Research & News
BEAT research
Company profile and research snapshot.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | HC Wainwright & Co. | Neutral | — |
| Jul 14, 2026 | Maxim Group | Buy | — |
| May 22, 2026 | HC Wainwright & Co. | Buy | — |
| May 15, 2026 | Benchmark | Speculative Buy | — |
| Mar 31, 2026 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 26, 2026
Acceptance into FDA’s TAP Pilot follows Breakthrough Device Designation granted earlier this month for HeartBeam’s heart attack assessment technologyTAP Pilot provides dedicated FDA advisors and early engagement with
Benzinga · Oct 21, 2026
HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million peopleData analysis is
Benzinga · Oct 15, 2026
HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortiumHeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studiesHEART-CHECK
ChartMill · Oct 6, 2026
In today's session, these stocks are experiencing unusual volume.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BEAT.
